生物利用度
化学
药物输送
异甘草素
肺表面活性物质
400号桩
Zeta电位
溶解度
色谱法
药品
药理学
生物化学
有机化学
纳米技术
材料科学
医学
聚乙二醇
纳米颗粒
作者
Kangyi Zhang,Qilong Wang,Qiuxuan Yang,Qiuyu Wei,Na Man,Michael Adu‐Frimpong,Elmurat Toreniyazov,Hao Ji,Jiangnan Yu,Ximing Xu
出处
期刊:Aaps Pharmscitech
[Springer Nature]
日期:2019-06-11
卷期号:20 (5)
被引量:31
标识
DOI:10.1208/s12249-019-1421-0
摘要
The aim of this study was to develop a self-microemulsifying drug delivery system (SMEDDS) for enhancement of the oral bioavailability of isoliquiritigenin (ISL) as well as evaluate its in vivo anti-hyperuricemic effect in rats. The ISL-loaded self-microemulsifying drug delivery system (ISL-SMEDDS) was comprised of ethyl oleate (EO, oil phase), Tween 80 (surfactant), and PEG 400 (co-surfactant). The ISL-SMEDDS exhibited an acceptable narrow size distribution (44.78 ± 0.35 nm), negative zeta potential (− 10.67 ± 0.86 mV), and high encapsulation efficiency (98.17 ± 0.24%). The in vitro release study indicated that the release rates of the formulation were obviously higher in different release media (HCl, pH 1.2; PBS, pH 6.8; double-distilled water, pH 7.0) compared with the ISL solution. The oral bioavailability of the ISL-SMEDDS was enhanced by 4.71 times in comparison with the free ISL solution. More importantly, ISL-SMEDDS significantly reduced uric acid level by inhibiting xanthine oxidase (XOD) activity in the model rats. Collectively, the prepared ISL-SMEDDS proved to be potential carriers for enhancing the solubility and oral bioavailability of ISL, as well as ameliorating its anti-hyperuricemic effect.
科研通智能强力驱动
Strongly Powered by AbleSci AI